Mateon Therapeutics Stock Price and Value Analysis

Should you buy Mateon Therapeutics stock? (Other OTC:MATN). Let's see how it does in our automated value investing analysis system.

AdvantagesDisadvantagesNeutral
  • This company has fluctuating growth.
  • This company is less known than others.
  • This stock looks overpriced.
  • This company is not making money.
  • This company pays no dividend.

Inside the MATN Numbers

MATN Price
(Mateon Therapeutics stock price per share)
$0.23
[?] PE Ratio versus Sector 100% lower than other Healthcare stocks
[?] PE Ratio versus Industry 100% lower than other Biotechnology stocks
[?] Free Cash Flow Jitter 35%

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 662,753 shares shorted. With 56,908,862 shares available for purchase and an average trading volume over the past 10 trading days of 421,914, it would take at least 1.571 days for all of the short holders to cover their shorts.

Is Mateon Therapeutics Stock on Sale?

Based on our analysis, we believe that you should not buy Mateon Therapeutics right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy MATN Stock?

Does Mateon Therapeutics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.